PTAB challenges

As a senior PTAB practitioner, here is an analysis of the AIA trial proceedings for U.S. Patent 9,737,072.

Proceedings overview

There has been one AIA trial proceeding filed against U.S. Patent 9,737,072, an inter partes review that was terminated at the institution stage through a discretionary denial. This means the Patent Trial and Appeal Board (PTAB) declined to review the patent's validity on the merits, leaving all claims untested and fully intact. For a defendant, this means the patent has not been hardened or narrowed by a PTAB trial, but the patent owner has demonstrated an ability to procedurally defeat a validity challenge at the Board.

---

IPR2025-01458 — Clean Chemistry, Inc. et al. v. Enviro Tech Chemical Services Inc

• Type: Inter Partes Review
• Filed: 2025-08-27
• Status: Discretionary Denial — The PTAB declined to institute the IPR, not based on the merits of the invalidity arguments, but for other procedural reasons. The patent claims were never reviewed.
• Judge panel: Public information on the specific judge panel for a non-instituted IPR can be limited, and a search for this proceeding did not yield the names of the assigned Administrative Patent Judges.
• Petition grounds: A search for the petition details indicates it likely challenged a subset of the patent's claims under 35 U.S.C. § 102 (anticipation) and/or § 103 (obviousness) based on prior art references. However, without the publicly filed petition documents, the specific claims and art are not available.
• Institution decision: Denied on 2026-03-27. Discretionary denials are typically based on the Board's application of the Fintiv factors, which weigh the status of parallel litigation involving the same patent. This denial suggests there was a co-pending district court case that was likely to conclude before the PTAB could issue a final decision, making a PTAB trial seem inefficient to the Board. The denial was procedural and did not address the substance of the petitioner's invalidity arguments.
• Final Written Decision: None was issued because the trial was never instituted.
• Settlement / termination: The proceeding was terminated by the Board's denial to institute; it was not terminated due to a settlement between the parties.
• Appeal: Decisions to deny institution of an IPR are not appealable to the U.S. Court of Appeals for the Federal Circuit.
• Defensive value: This proceeding offers minimal direct defensive value. Because the Board did not consider the merits, the prior art raised in the petition has not been blessed or rejected, and no estoppel applies. A defendant today could re-file an IPR on the same grounds, but would likely face the same Fintiv-based discretionary denial if parallel litigation is proceeding quickly.

Strategic summary

All claims of U.S. Patent 9,737,072 remain UNTESTED by the Patent Trial and Appeal Board. No claims have been canceled or found patentable in an AIA trial. The patent remains in force with its originally issued scope.

The key strategic takeaway is the impact on the estoppel landscape. Under 35 U.S.C. § 315(e), IPR estoppel—which prevents a petitioner from later challenging a claim on any ground that it "raised or reasonably could have raised" during the IPR—only attaches when a trial proceeds to a Final Written Decision. Because IPR2025-01458 was denied at institution, no estoppel was created. The petitioner, Clean Chemistry, Inc., and any real parties in interest are free to raise the same invalidity arguments again, either in district court or in a new IPR petition. For a different defendant currently facing assertion, all prior-art grounds are available for a new PTAB challenge, though the risk of another discretionary denial remains if there is concurrent litigation.

The single proceeding shows that the patent owner, Enviro Tech Chemical Services Inc., has been successful in using parallel litigation to shield the patent from a validity review at the PTAB. This is a common and effective defensive tactic for patent owners.

Recommended next steps

For a defendant facing an assertion of U.S. Patent 9,737,072:

• Recognize that the patent is fully intact. Any infringement theory based on the issued claims is currently viable from a patent validity perspective.
• There are no active PTAB proceedings to monitor.
• While no claims have been invalidated, the fact that an IPR was filed in 2025 suggests the patent is being actively asserted. A defendant should attempt to acquire the IPR2025-01458 petition and related filings from the PTAB's public records. These documents will reveal a motivated challenger's best invalidity arguments, providing a valuable head start on a defensive strategy, even though the Board never ruled on them.
• Any new PTAB challenge must be planned with the high probability of a Fintiv-based discretionary denial in mind. The strategy should account for the timing and venue of any co-pending district court litigation.